β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F20%3A10415901" target="_blank" >RIV/00216208:11130/20:10415901 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/20:10415901

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=a65C-Uh7us" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=a65C-Uh7us</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1212/WNL.0000000000010943" target="_blank" >10.1212/WNL.0000000000010943</a>

Jazyk výsledku

angličtina

Název v původním jazyce

β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies

Popis výsledku v původním jazyce

OBJECTIVE: In a multi-center cohort of probable dementia with Lewy bodies (DLB), we tested the hypothesis that amyloid-β and tau biomarker positivity increases with age, which is modified by APOE genotype and sex, and that there are isolated and synergistic associations with the clinical phenotype. METHODS: We included 417 DLB patients (45-93 years, 31% women). Positivity on amyloid-β (A+) and tau (T+) biomarkers was determined by cerebrospinal fluid amyloid-β 1-42 and phosphorylated tau in the European cohort, and Pittsburgh compound-B and AV-1451 positron emission tomography in the Mayo Clinic cohort. Patients were stratified into 4 groups: A-T-, A+T-, A-T+, A+T+. RESULTS: A-T- was the largest group (39%), followed by A+T- (32%), A+T+ (15%), and A-T+ (13%). The percentage of A-T- decreased with age and A+ and T+ increased with age both in women and men. A+ increased more in APOE ε4 carriers with age than in non-carriers. A+ was the main predictor of lower cognitive performance when considered together with T+. T+ was associated with a lower frequency of parkinsonism and probable rapid eye movement sleep behavior disorder. There were no significant interactions between A+ and T+ in relation to the clinical phenotype. CONCLUSIONS: Alzheimer&apos;s disease pathologic changes are common in DLB and are associated with the clinical phenotype. Amyloid-β is associated with cognitive impairment and tau pathology is associated with lower frequency of clinical features of DLB. These findings have important implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in patients with probable DLB, amyloid-β is associated with lower cognitive performance and tau pathology is associated with lower frequency of clinical features of DLB.

Název v anglickém jazyce

β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies

Popis výsledku anglicky

OBJECTIVE: In a multi-center cohort of probable dementia with Lewy bodies (DLB), we tested the hypothesis that amyloid-β and tau biomarker positivity increases with age, which is modified by APOE genotype and sex, and that there are isolated and synergistic associations with the clinical phenotype. METHODS: We included 417 DLB patients (45-93 years, 31% women). Positivity on amyloid-β (A+) and tau (T+) biomarkers was determined by cerebrospinal fluid amyloid-β 1-42 and phosphorylated tau in the European cohort, and Pittsburgh compound-B and AV-1451 positron emission tomography in the Mayo Clinic cohort. Patients were stratified into 4 groups: A-T-, A+T-, A-T+, A+T+. RESULTS: A-T- was the largest group (39%), followed by A+T- (32%), A+T+ (15%), and A-T+ (13%). The percentage of A-T- decreased with age and A+ and T+ increased with age both in women and men. A+ increased more in APOE ε4 carriers with age than in non-carriers. A+ was the main predictor of lower cognitive performance when considered together with T+. T+ was associated with a lower frequency of parkinsonism and probable rapid eye movement sleep behavior disorder. There were no significant interactions between A+ and T+ in relation to the clinical phenotype. CONCLUSIONS: Alzheimer&apos;s disease pathologic changes are common in DLB and are associated with the clinical phenotype. Amyloid-β is associated with cognitive impairment and tau pathology is associated with lower frequency of clinical features of DLB. These findings have important implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in patients with probable DLB, amyloid-β is associated with lower cognitive performance and tau pathology is associated with lower frequency of clinical features of DLB.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neurology

ISSN

0028-3878

e-ISSN

—

Svazek periodika

95

Číslo periodika v rámci svazku

24

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

"e3257"-"e3268"

Kód UT WoS článku

000607315800022

EID výsledku v databázi Scopus

2-s2.0-85098531149